Antibio3.0

Equipe(s)
Agence de moyen
Etat
Titre du projet
Therapeutic innovation in drug discovery: new anti microbial molecules targeting a specific bacterial protein
Nom de l'appel d'offre
AAPG2020
DĂ©fi/axe ANR
CES18
Coordinateur.trice
N. RamaRao Micalis Jouy-en-Josas
Participants de MaIAGE
G. André-Leroux
Année de démarrage - Année de fin de projet
2021
Date de fin du projet
Résumé
Antibiotics have drastically reduced the mortality associated with infectious diseases. Yet, their effectiveness and easy access led to misuse and overuse, prompting bacteria to develop resistance. Currently, antibiotics are usually based on essential bacterial pathways, and therefore cover a broad spectrum of bacteria. There is however a high risk of resistance development, leading to a dramatic health issue and new medicines are thus urgently needed. A major challenge for efficient drug design is to find and characterize the appropriate bacterial targets. We have a new target which is patented and we have hits responsible of its specific inhibition in vitro and in vivo. We want to decipher their mode of action in cristalo, in silico and in vivo, in order to potentiate them into lead molecules, while enlarging the bacterial range to priority pathogens of the ESKAPE group.
Année de soumission
2019